Kevzara (sarilumab) is an antibody pharmaceutical. Sarilumab was first approved as Kevzara on 2017-05-22. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
|Drug Class||Monoclonal antibodies: fully human, immunomodulating|